

USTUR Special Session
61st Annual Meeting of the Health Physics Society
Spokane, WA, July 19, 2016

USTUR Case 0785: Modeling Pu Decorporation Following Complex Exposure

Sara Dumit, Maia Avtandilashvili, Bastian Breustedt,
Sergei Y. Tolmachev

United States Transuranium and Uranium Registries
College of Pharmacy, Washington State University

*“Learning from Plutonium and
Uranium Workers”*





Objectives

- Plutonium biokinetic modeling under decorporation treatment
- Estimating intake and dose



USTUR Case 0785

- Primary exposure: Plutonium (Pu)
- Exposure scenario: Acute inhalation and wound
- Material type: M (assumed)
- Smoking status: 38 y (0.5 pack per day)
- Cause of death: Lung disease
- Post-intake: 51 y
- Age: 79 y



Case 0785 Accident

- Working with plutonium nitrate solution
- Glove-box explosion
- Face, hair, neck, hands, and forearms contamination
- Facial wound deposition 8,032 Bq
- Plutonium systemic burden 7,400 Bq (worksite)

Five times higher than MPBB



Treatment

Decorporation Therapy

- Immediately: 1-2 g Ca-EDTA, 2 i.v. per day, 4 weeks
- 9 months post-accident: 2 g Ca-EDTA, 2 i.v. per day, 2 weeks
- 7 years post-accident: 1 g Zn-DTPA, 1 i.v. per week, 10 weeks





Wound Excision

- 3 weeks post-accident: 7,344 Bq of plutonium was removed



Bioassay Measurements

- In-vivo: 74 lung counts
- In-vitro: 478 urinalyses





Autopsy Tissue Analysis

- Total of 32 tissue samples
- $^{238,239+240}\text{Pu}$ concentration measured
- Total tissue/organ activity estimated

Tissue/Organ	$^{239+239}\text{Pu}$ Concentration, Bq kg ⁻¹	$^{239+240}\text{Pu}$ Activity, Bq
Lungs	18.2 ± 0.3	24.6 ± 0.4
LNTH	5,884 ± 98	108.7 ± 1.8
Liver	548 ± 36	602.0 ± 40
Skeleton	209 ± 8	1,936 ± 74
Total Systemic	-----	2,728 ± 84

- LNTH:Lung concentration ratio = 323
- Exposure to very insoluble material (Super S)



Data Analysis

Biokinetic Models


- ICRP Human Respiratory Tract Model (ICRP 130)
- NCRP Wound Model (NCRP 156)
- Leggett Plutonium Systemic Model (Leggett et al, 2005)

Assumptions




- Particle size: 1 μm AMAD
- Lung absorption type: S
- Wound retention category: insoluble colloid



IMBA Professional Plus®




- A suite of software modules for internal dosimetry
- Implements all current biokinetic and dosimetric models
- Enables the user to:
 - ✓ Estimate an intake from bioassay measurement data
 - ✓ Predict bioassay quantities from a specific intake
 - ✓ Calculate resulting doses





Residual Intake Estimation

Activity not removed by chelation therapy



- Inhalation: 33,050 Bq (97%)
- Wound: 1,084 Bq (3%)



Total Intake and Dose Estimation

- Intake

- ✓ Residual intake: 34,134 Bq
- ✓ Pu removed by chelation: 683 Bq

$$\begin{array}{r} + \\ 34,134 \text{ Bq} \\ 683 \text{ Bq} \\ \hline 34,817 \text{ Bq} \end{array}$$

- Committed Effective Dose

- ✓ Residual CED: 1.09 Sv
- ✓ Projected CED: 1.11 Sv



Conclusions

- Exposure to highly insoluble Pu material
- Systemic deposition 51 years post-intake was 2,728 Bq with skeleton-to-liver activity ratio of 3:1
- Major internal contamination (97%) from inhalation
- Estimated intake was 34,817 Bq
- Estimated committed effective dose: 1.09 Sv
- Only 2% dose was saved by decorporation treatment



Thank you! Questions?

